A recent tribunal saw a generic drug manufacturer deploy significant metaphorical firepower in a patent infringement trial against Pacira Biosciences Inc. The crux of their argument revolved around the claim that the information provided in Pacira’s painkiller patent represented merely the “tip of the iceberg”.
The legal team for the generic drug maker posited that the complete data regarding the medicine, if disclosed in its entirety, would have led regulators to reject Pacira’s initial patent application. The adopted “iceberg” narrative is intended to underline the alleged disparity between the provided information and what they deem should have been disclosed.
As matters stand, the complex details of the trial continue to unfold. To glean further insights into this legal maneuver, one can refer to the reporting done on the case here.